Tanja Obradovic, Therapeutic Strategy Lead of Oncology at Novotech, Senior Advisor of Oncology Drug Development at HopeAI, shared a post on LinkedIn:
“Early stage non-small-cell lung cancer (NSCLC) may see several key read-outs. Some that peaked interest before we see full Abstracts on May 21st:
LIBRETTO-432, a phase III study of adjuvant selpercatinib (highly selective and potent central nervous system-active RET kinase inhibitor) or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer. Primary end point is investigator-assessed event-free survival (EFS) in the primary analysis population (stage II-IIIA RET fusion-positive NSCLC). Key secondary end points include EFS in the overall population, overall survival, and time to distant disease recurrence in the central nervous system. If positive this can become new standard of care in IB-IIIA RET fusion-positive NSCLC. (Abstract LBA3, Plenary session).
Beamion LUNG-3: Zongertinib (irreversible TKI) in resectable NSCLC patients with stage II-IIIB who have HER2 (ERBB2) mutations in the tyrosine kinase domain. In February FDA granted accelerated approval to zongertinib based on outstanding results of Beamion LUNG-1 trail so now data from Phase III will describe in more detail this new standard of care. (Abstarct TPS8129)
Adebrelimab (PD-L1 inhibitor) in combination with anlotinib (angiokinase inhibitor) and chemotherapy as neoadjuvant therapy for resectable stage II-III non–small cell lung cancer (NSCLC): A prospective, single-arm, phase II trial. Initial results from Phase I trial indicated good regiment tolerability and encouraging efficacy so expanded data set strength coming from this report will chart future possibility toward new treatment paradigm (Abstract e2007).
Comparative analysis of neoadjuvant chemoimmunotherapy (chemoIO) versus PD-(L)1 monotherapy (mono) across PD-L1 expression strata in resectable non–small cell lung cancer (NSCLC): A systematic review and meta-analysis of prospective trials. This report will shed more light into critical decision choices. Abstract (e20069)
Prognostic stratification of early-stage NSCLC patients using preoperative circulating tumor DNA (ctDNA). This report will add to our knowledge of ctDNA utility in early stage NSCLC where easier diagnostics guiding improved treatment options remains area of high hopes. (Abstract 8031).”
Nearly Half of Older Adults With Metastatic NSCLC Never Received Systemic Therapy
